nach oben

Supportive Care in Cancer

Erschienen in:

01.10.2010 | Original Article

Validation of EQ-5D in patients with cervical cancer in Taiwan

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The survival rate of cervical cancer is increasing due to early diagnosis and timely treatment. As a result, the availability of a valid and reliable general HRQoL is important. The purpose of this study was to evaluate the psychometric properties of the EuroQol questionnaire (EQ-5D) in patients with cervical cancer in Taiwan.

Method

Outpatients with cervical cancer were recruited from three medical centers across Taiwan. Test–retest reliability and ceiling effect were evaluated. Construct validity including convergent and discriminate validities were examined using the EORTC QLQ C-30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and the clinical indicators of the functional performance assessment using the Karnofsky Performance Scale (KPS) and disease status.

Results

A total of 530 patients completed the questionnaire. The intraclass correlation coefficient for the EQ-5D index was 0.83, and the Cohen's kappa values for the EQ-5D dimensions ranged from 0.54 to 0.73. The EQ-5D index and VAS scores were higher for patients with a higher KPS score and disease-free status. The EQ-5D index was strongly correlated with all EORTC QLQ-C30 functioning scales.

Conclusion

The EQ-5D questionnaire is reliable and valid for the assessment of health-related quality of life in patients with cervical cancer in Taiwan.

Division of Statistics DOH (2005) Statistics of causes of death, health and vital statistical. In: Editor ED (ed) Book of statistics of causes of death, health and vital statistical. Department of Health, Executive Yuan, R.O.C. Taipei

Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, Weiderpass E (2004) Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 91:935–941PubMed

Hou SI, Fernandez ME, Baumler E, Parcel GS, Chen PH (2003) Correlates of cervical cancer screening among women in Taiwan. Health Care Women Int 24:384–398PubMed

Liao CC, Wang HY, Lin RS, Hsieh CY, Sung FC (2006) Addressing Taiwan's high incidence of cervical cancer: factors associated with the Nation's low compliance with Papanicolaou screening in Taiwan. Public Health 120:1170–1176CrossRefPubMed

Nayfield SG, Ganz PA, Moinpour CM, Cella DF, Hailey BJ (1992) Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1:203–210CrossRefPubMed

Osoba D (1992) The quality of life committee of the clinical trials group of the national cancer institute of Canada: organization and functions. Qual Life Res 1:211–218CrossRefPubMed

Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C (2003) Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 56:52–60CrossRefPubMed

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed

Gold MR, Patrick DL, Torrance DG (1996) Identifying and valuing outcomes. In: Gold MR (ed) Cost-effectiveness in health and medicine. Oxford University Press, New York, pp 82–134

10.

Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27:S217–S232CrossRefPubMed

11.

Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343CrossRefPubMed

12.

Badia X, Schiaffino A, Alonso J, Herdman M (1998) Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 7:311–322CrossRefPubMed

13.

Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736–741PubMed

14.

Drummond M (2001) Introducing economic and quality of life measurements into clinical studies. Ann Med 33:344–349CrossRefPubMed

15.

Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ (2004) Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 13:1247–1253CrossRefPubMed

16.

Anderson H, Palmer MK (1998) Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer 77(Suppl 2):9–14PubMed

17.

Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schroder FH (1998) Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 90:925–931CrossRefPubMed

18.

Polsky D, Keating NL, Weeks JC, Schulman KA (2002) Patient choice of breast cancer treatment: impact on health state preferences. Med Care 40:1068–1079CrossRefPubMed

19.

Trippoli S, Vaiani M, Lucioni C, Messori A (2001) Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life study group of the master 2 project in pharmacoeconomics. Pharmacoeconomics 19:855–863CrossRefPubMed

20.

van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222–229CrossRefPubMed

21.

Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32(Suppl):S66–S81CrossRefPubMed

22.

Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72CrossRefPubMed

23.

Essink-Bot ML, Stouthard ME, Bonsel GJ (1993) Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Econ 2:237–246CrossRefPubMed

24.

Kind P (1996) The EuroQol instrument: an index of health-related quality of life. In: Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven Publishers, Philadelphia, pp 191–201

25.

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRefPubMed

26.

Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P (1998) Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 9:549–557CrossRefPubMed

27.

Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, Kvikstad A (1995) The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 31A:2260–2263CrossRefPubMed

28.

Karnofsky DA, Burchenal JH (1950) Present status of clinical cancer chemotherapy. Am J Med 8:767–788CrossRefPubMed

29.

Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135–1141CrossRefPubMed

30.

Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 53:2002–2007CrossRefPubMed

31.

Juniper EF, Gordon HG, Roman J (1996) How to develop and validate a new health-related quality of life instrument. In: Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven Publishers, Philadelphia, pp 49–56

32.

Brazier J, Jones N, Kind P (1993) Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 2:169–180CrossRefPubMed

33.

Nunnally JC, Bernstein IH (1994) Psychometric theory. McGraw-Hill, NY

34.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed

35.

Savoia E, Fantini MP, Pandolfi PP, Dallolio L, Collina N (2006) Assessing the construct validity of the Italian version of the EQ-5D: preliminary results from a cross-sectional study in North Italy. Health Qual Life Outcomes 4:47CrossRefPubMed

Titel: Validation of EQ-5D in patients with cervical cancer in Taiwan
Publikationsdatum: 01.10.2010
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0745-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Validation of EQ-5D in patients with cervical cancer in Taiwan

Abstract

Purpose

Method

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer

Spinal analgesia: where is the evidence?

The ties that bind: a reflection on physician grief

Efficacy of multifaceted interventions in reducing complications of peripherally inserted central catheter in adult oncology patients

Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study

Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie